Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price was down 3.5% during mid-day trading on Thursday . The stock traded as low as $202.85 and last traded at $205.25. Approximately 1,618 shares changed hands during trading, a decline of 41% from the average daily volume of 2,749 shares. The stock had previously closed at $212.80.
Genmab A/S Stock Performance
The firm has a market capitalization of $13.42 billion, a PE ratio of 19.74 and a beta of 1.03. The company’s 50-day moving average price is $220.80 and its 200-day moving average price is $248.86.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- Where Do I Find 52-Week Highs and Lows?
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
